A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
← catalyst calendarNCT07633470 · readout ≤ 254 d
Sponsored by Alpha Cognition, Inc (industry) · ACOG — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
150estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-20 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer Disease
Intervention
- Drug: Zunveyl® — also filed as Benzgalantamine
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured From Week 1 up to Week 12
Percentage of Participants who Discontinued due to AEs
measured From Week 1 up to Week 12
Number of Participants with Treatment Interruptions or Dose Reductions
measured From Week 1 up to Week 12
Global Tolerability Score
measured At Weeks 1, 2, 4, 6, 8 12, and 17
Permalink · ACOG's whole pipeline · Catalyst calendar · Every registered study · What changed